Sanofi Issues Bonds to Fund Genzyme Acquisition - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Sanofi Issues Bonds to Fund Genzyme Acquisition

ePT--the Electronic Newsletter of Pharmaceutical Technology

On Mar. 23, 2011, sanofi-aventis offered $7 billion in notes to fund its acquisition of Genzyme. The notes are offered in six tranches scheduled to come due between 2012 and 2021, and the interest rates range from 0.05% to 4%.

Sanofi-aventis named BNP PARIBAS, Bank of America–Merrill Lynch, J.P. Morgan, Société Générale, Crédit Agricole CIB, Deutsche Bank Securities, HSBC, RBS, and Santander as joint book runners for the offering in a press release. Standard and Poor’s rated sanofi AA-, and Moody’s rated the company A2.

If sanofi does not complete the exchange offer for Genzyme shares by Sept. 30, 2011, the company will redeem all the fixed-rate notes and the 2014 floating-rate notes at 101% of par value plus accrued interest by Oct. 31, 2011. Sanofi will use the remaining proceeds from the 2012 floating-rate notes and the 2013 floating-rate notes for general corporate purposes.

In related news, problems in the fill–finish process for Genzyme’s Fabrazyme product will affect patients’ access to the drug. Quality-assurance personnel rejected one lot of Fabrazyme produced at Genzyme’s Allston Landing, Massachusetts, facility, because it did not meet release criteria. The company will fill and finish all future lots of the drug at a contract-manufacturing facility that is performing this operation already.

“Because inventory is so limited, loss of this specific lot of Fabrazyme will have an impact on some patients in the coming months,” said Genzyme in a press release. Some patients may have to delay scheduled infusions immediately, and others may miss one or more infusions during the next few months. The supply reduction will affect all regions, according to the company. Nevertheless, Genzyme is “still on track to return to normal supply of Fabrazyme in the second half of 2011 with the expected approval of our new manufacturing facility in Framingham, Massachusetts,” according to the press release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here